Bintie Biotechnology
Advancing biomedical innovation with groundbreaking immune cell therapies for targeting solid tumors.
Advancing biomedical innovation with groundbreaking immune cell therapies for targeting solid tumors.
Bintie Biotechnology is a pioneering biomedical technology enterprise founded in 2021 that focuses on advancing biomedical innovation with groundbreaking immune cell therapies for targeting solid tumors. With its primary products being novel immune cell formulations, the company operates within the Biotechnology industry.
The latest milestone for Bintie Biotechnology was a CNY100.00M Series A investment at 31 October 2023, which was backed by notable investors including SDIC Ventures, Winguide Huangpu Pharmaceutical, and Yuanxi Haihe Fund.
This recent investment signifies a vote of confidence from the venture capital community and highlights the potential seen in Bintie Biotechnology's innovative approach to immune cell therapies for solid tumors.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | CNY100.00M | 3 |
|
31 Oct 2023 |
No recent news or press coverage available for Bintie Biotechnology.
We care about your data, and we'd love to use cookies make your experience better.